| abstract |
REFERRING TO A PYRIDINE COMPOUND OF FORMULA (I), WHERE X IS N AND Y IS CH, OR X IS CH E Y IS N; Z IS O, S, SO, or SO2; R1 IS CO2H, CH2CO2H, TETRAZOLE, AMONG OTHERS; R2a AND R2b ARE H, HALO, CN, NO2, AMONG OTHERS; R3a AND R3b ARE H, HALO, C1-C8 ALKYL, AMONG OTHERS; Rx IS ALKYL, ALKENYL, ALKINYL, AMONG OTHERS; R8 IS H, FLUOR OR ALKYL; R9 IS H, HYDROXY, FLUOR, ALKYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: 6 - [(5-CHLORO-2 - {[(4-CHLORO-2-FLUOROPHENYL) METHYL] OXY} PHENYL) METHYL] -2-PYRIDINECARBOXYL ACID, 6 - ({5-CHLORO-2- [(2-METHYL-2-PROPEN-1-IL) OXY] PHENYL} METHYL) -2-PYRIDINECARBOXYL, 6 - [(5-CHLORO-2 - {[(2,4-DIFLUOROPHENYL) METHYL] OXY} PHENYL) SODIUM METHYL] -2-PYRIDINECARBOXYLATE, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE ANTAGONISTS OF THE EP1 RECEPTOR AND ARE USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY PGE2 PROSTAGLANDINS SUCH AS ACUTE AND CHRONIC PAIN, NEUROPATHIC PAIN, CHRONIC JOINT PAIN, AMONG OTHERS |